SCHEMBL5485261

SCHEMBL5485261

O=C1Nc2occc2C1(c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
KCNH2 Q12809 1/20 0.53
GPR55 Q9Y2T6 4/20 0.48
CNR1 P21554 3/20 0.48
HTT P42858 1/20 0.48
GPR35 Q9HC97 1/20 0.48
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
PKM P14618 1/20 0.36
LMNA P02545 5/20 0.35
MAPT P10636 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TYMS P04818 2/20 0.35
ALDH1A1 P00352 1/20 0.35
ESR1 P03372 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478018 0.80 ALDH1A1 (0.38) CHRM2ADORA3KCNH2GPR55CNR1
SCHEMBL5481283 0.78 MAPT (0.60) HTTPKMLMNAMAPTMEN1
SCHEMBL5474337 0.78 SMN1; SMN2 (0.60) HTTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5482451 0.76 SMN1; SMN2 (0.38) HTTLMNAMAPTSMN1; SMN2ALDH1A1
SCHEMBL5482166 0.73 CHRM2 (0.49) CHRM2ADORA3KCNH2GPR55CNR1
Oxyphenisatine SCHEMBL239513 0.69 CHRM2 (1.00) CHRM2ADORA3KCNH2GPR55CNR1
Oxyphenisatine SCHEMBL35387956 0.69 CHRM2 (1.00) CHRM2ADORA3KCNH2GPR55CNR1
SCHEMBL5488424 0.67 CNR1 (0.51) CHRM2ADORA3KCNH2GPR55CNR1
SCHEMBL2716060 0.67 CHRM2 (0.93) CHRM2ADORA3KCNH2GPR55CNR1
SCHEMBL5486744 0.67 CHRM2 (0.53) CHRM2ADORA3KCNH2GPR55CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CHRM2 2994/4885ADORA3 3566/4885KCNH2 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.